Results 131 to 140 of about 49,282 (280)

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5‐year perspective from an EQA provider

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 445-456, February 2026.
Aims Pharmacogenetic implementation requires awareness of the state‐of‐the‐art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco‐scheme established ...
Rossana Roncato   +8 more
wiley   +1 more source

Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 589-605, February 2026.
Aims Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar ...
Junjie Ding   +24 more
wiley   +1 more source

Influence of 5-HT3bReceptor AAG Deletion Mutation and CYP2D6*10 on the Ondansetron Treatment [PDF]

open access: bronze, 2006
Ju‐Hee Kang   +7 more
openalex   +1 more source

Chemical Profiling, In Silico and In Vitro Studies to Identify Potential CDK2 and mTOR Inhibitor From Selaginella inaequalifolia (Hook. & Grev.) Spring Ethanolic Extracts

open access: yesChemistry &Biodiversity, Volume 23, Issue 2, February 2026.
ABSTRACT The current study is aimed to reveal the phytoprofile of Selaginella inaequalifolia (Hook. & Grev.) Spring using GC–MS and predict the drug properties, toxicity, biological properties of S. inaequalifolia ethanolic extracts (SiEE) using in silico methods and in vitro toxicity assays, namely, MTT and BSLB assay.
Johnson Marimuthu Alias Antonysamy   +4 more
wiley   +1 more source

CYP2D6*2N Allele

open access: hybrid, 2020
National Cancer Institute
openalex   +1 more source

Metabolite Profiling and Anticancer Evaluation of Iraqi Haloxylon articulatum Halophyte via LC–HRMS/MS, Molecular Docking, and ADMET Analysis

open access: yesChemistry &Biodiversity, Volume 23, Issue 2, February 2026.
This study investigates the phytochemical composition and biological activities of a hydroalcoholic extract of Haloxylon articulatum. LC‐HRMS/MS identified diverse bioactive compounds, notably N‐caffeoyltyramine and sinapoyltyramine. The extract exhibited strong antioxidant activity and significant cytotoxic effects against gastric cancer cell lines ...
Jihen Abidi   +6 more
wiley   +1 more source

Acute Liver Failure With Transient Liver Steatosis Following Multiple Hits Postoperatively in a Patient With Limb‐Girdle Muscular Dystrophy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Transient liver steatosis is rarely described. A fast development of liver steatosis leading to acute liver failure (ALF) is, to our knowledge, rarely observed. It is so far observed and published in acute fatty liver of pregnancy, and in a few cases of ALF. However, it is observed in elective surgery for pancreaticoduodenectomy and some cases
Anders Benjamin Kildal   +7 more
wiley   +1 more source

Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes [PDF]

open access: bronze, 2001
Chiaki Senda   +7 more
openalex   +1 more source

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 375-380, February 2026.
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Joseph Piscitelli   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy